ReviewArchives of pharmacal research2021
Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
Review in Archives of pharmacal research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 37 citations in OpenAlex.
- [Determination of 65 synthetic cannabinoids in whole blood by QuEChERS-ultra performance liquid chromatography- mass spectrometry].Se pu = Chinese journal of chromatography · 2026Article
- Acute and subacute cardiovascular effects of synthetic cannabinoid JWH-018 in rat.Forensic toxicology · 2025Article
- Clinical and Public Health Challenge of Handling Synthetic Cathinone and Cannabinoid Abuse in Pediatric Care: A Narrative Review.Pediatric reports · 2025Review
- Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice.Journal of veterinary science · 2024Article
- Acute, chronic, and post-mortem toxicity: a review focused on three different classes of new psychoactive substances.Forensic toxicology · 2023Review
- Characterization of URB Series Synthetic Cannabinoids by HRMS and UHPLC-MS/MS.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Endocannabinoid System as a Target for Neuroprotection/Neuroregeneration in Perinatal Hypoxic-Ischemic Brain Injury.Biomedicines · 2022Review
- Development and validation of the UPLC-MS method for simultaneous determination of six new psychoactive substances.RSC advances · 2022Article
- Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.Biomedicines · 2022Review
- Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?Cells · 2022Review
- Synthetic cannabinoid JWH-073 alters both acute behavior andFrontiers in psychiatry · 2022Article
- Cannabidiol modulation of oxidative stress and signalling.Neuronal signaling · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Over the last decade, new psychoactive substances (NPS) have continuously been the focus of the international society since their emergence on the illicit drug market. NPS can be classified into six groups including; synthetic cannabinoid receptor agonists (SCRAs), stimulants, opioids, dissociatives, sedatives/hypnotics, and classic hallucinogens with psychoactive effects. These are sold as "herbal incense," "bath salts," "legal highs," and "research chemicals". They can be synthesized easily with slight changes in the chemical moieties of known psychoactive substances. NPS are sold worldwide via on- and off-line markets without proper scientific evaluation regarding their safety or harmfulness. Abuse of NPS poses a serious public health issue, and systematic studies on their adverse effects are lacking. Therefore, it would be meaningful to collect currently available data in order to understand NPS and to establish viable solutions to cope with the various health issues related to them. In this article, we reviewed the general pharmacological characteristics, recent findings, and adverse effects of representative NPS; SCRAs. SCRAs are known as the most commonly abused NPS. Most SCRAs, cannabinoid receptor 1 and cannabinoid receptor 2 agonists, are often associated with severe toxicities, including cardiotoxicity, immunotoxicity, and even death, unlike natural cannabinoid Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.